Antiepileptic drugs are therapies approved to treat patients with epilepsy, a brain disorder in which clusters of nerve cells signal abnormally, which can lead to seizures. These seizures are incidents that occur when group of nerve cells or neurons in brain sends wrong signals. Patients suffering from epilepsy may complain about strange emotions and sensations or they may behave strangely. Epilepsy is the fourth most common brain disorder affecting people of all ages. The causes of epilepsy are undetermined however major risk factors involved include brain injury, brain tumor, stroke, and substance use disorders.

View Report: https://www.transparencymarketresearch.com/antiepileptic-drugs-market.html

For the treatment of epilepsy, antiepileptic medicines (AEDs) are prescribed, preference of the drug depending on the age of the patient, type of seizures to be treated, seriousness of the seizures, and part of the brain involved. Alcoholism, smoking, changing lifestyle and rising geriatric population are the major factor driving the antiepileptic market.

The market for antiepileptic drugs is broadly classified on the basis of first generation antiepileptic drugs and second generation antiepileptic drugs and pipeline drugs. First generation antiepileptic drugs consists of Valproate (Depakote), Oxycarbazepine ((Trileptal), Carbamazepine (Carbatrol), Phenobarbital (Luminal), Primidone (Mysoline), Ethosuximide (Zarontin), Topiramate (Topamax) Phenytoin (Dilantin, Phenytek). Second generation antiepileptic drugs consist of different mechanism of action than the first generation drugs. These consists of Lamotrigine (Lamictal), Pregabalin (Lyrica), Eslicarbazepine acetate Zonisamide (Zonegran), Lacosamide (Vimpat), Levetiracetam (Keppra), (Aptiom/Zebinix), Perampanel (Fycompa), Rufinamide (Banzel/Inovelon), Ezogabine/retigabine (Trobalt/Potiga),. First generation antiepileptic drugs majorly carbamazepine, valproate, phenytoin and oxycarbazepine are dominating the epilepsy therapeutics market. However, second generation AEDs such as levetiracetam, zonisamide and lacosamide are slowly overtaking the antiepileptic drugs market due to its improved tolerability and efficacy.

Request a Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7664

The pipeline for antiepileptic drugs has been segmented on different phases. The drugs in the phase III of the pipeline include Brivaracetam (UCB Pharma Ltd), Ganaxolone (Marinus Pharmaceuticals), USL261 (Upsher Smith Laboratories, Inc.), Perampanel (Eisai Co) and YKP3089 (SK Life Sciences) and others. The phase I and II of the pipeline drugs include Buspirone, Everoline, UCB0942 (PPSI), Lacosamide, GWP42006, TAK-932 and others. All this drugs are currently under clinical trials and it is expected that these drugs will prove beneficial for epilepsy therapeutics market.

Geographically, North America dominates the global antiepileptic drugs market followed by Europe majorly due to the extensive research and development activities in the neurology and the presence of pharmaceutical industries in the region. Epilepsy affects approximately 2.5 million people in the United States, and results in an estimated annual cost of approximately $15.5 billion in healthcare. Three new antiepileptic drugs have been approved in U.S. since 2012 including ezogabine/retigabine, perampanel and eslicarbazepine acetate. Continuous increase in uptake of second generation antiepileptic drugs is also driving the antiepileptic drugs market in North America and Europe. Asia-Pacific is also increasing constantly in the antiepileptic drugs market mainly due to the high prevalence of epilepsy in India and China, increased penetration due to better market access options in China and expected approval of drugs with novel mechanisms are some of the factors responsible for expanding the epilepsy therapeutics market in the Asia-Pacific region. Latin America is also a growing market for antiepileptic drugs due to developing healthcare expenditure and high prevalence rate of epilepsy in the region.

Request TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=7664

Some of the major players in epilepsy therapeutics market include Abbott Laboratories, Cephalon, Inc, GlaxoSmithKline plc,., Johnson & Johnson, Novartis AG, Pfizer, Inc., Sunovion Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Sanofi S.A. and UCB Pharma Ltd.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

Contact Us

Transparency Market Research

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com